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Abstract
Background: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the
strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent
paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that
it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto,
and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy.
Methods: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for
growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve
growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application
of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt
via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells
using MTT assay.
Results: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite
length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12
cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF
promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor
or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when
Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto
promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other
hand, Kamishoyosan or Shakuyakukanzoto didn’t influence cytotoxicity of paclitaxel in A549 cells.
Conclusions: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the
proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from
paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without
influence of anticancer effect of paclitaxel.
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Background
In chemotherapy, dose intensity is highly important, since
antitumor agents are ineffective, but still carry significant
risk, when the amount delivered is suboptimal [1]. Pacli-
taxel, a key chemotherapeutic used against many solid
cancers, induces neuropathy as a side effect as frequently
as 50% of the time in a cumulative, dose-dependent man-
ner [2, 3]. This neurotoxicity significantly and negatively
influences treatment, and may necessitate shortening or
otherwise limiting such treatment. Paclitaxel promotes
microtubule assembly, which damages both cancer cells
and neurons alike. When damaging neurons, it does not
normally penetrate the blood brain barrier, but instead
produces peripheral neuropathy [4]. Shakuyakukanzoto,
an herbal formula utilized in kampo medicine, is currently
approved for the treatment of muscle spasms. Recently,
Hidaka et al. reported that Shakuyakukanzoto may sup-
press paclitaxel-induced allodynia in vivo, though they
were unable to elucidate the mechanisms underlying this
effect [5]. Another formula, Goshajinkigan, has also been
reported to potentially reduce oxaliplatin-induced periph-
eral neuropathy [6, 7]. The present study aimed to test
whether Shakuyakukanzoto, Kamishoyosan, which which
also contains all the ingredients of Shakuyakukanzoto, or
Goshajinkigan could promote recovery from paclitaxel-
induced neuropathy. We further aimed to elucidate the
mechanisms underlying these potential effects.
Methods
Materials
PC12 cells, penicillin, and streptomycin were purchased
from DS Pharma Biomedical Co., Ltd. (Osaka, Japan).
Dulbecco’s modified Eagle medium (DMEM) and the
Amplite colorimetric acetylcholinesterase assay kit were
purchased from NACALAI TESQUE, INC (Kyoto, Japan).
Fetal bovine serum (FBS) and horse serum (HS) were pur-
chased from Biowest (Nuaillé, France). Paclitaxel, NGF,
and GAP-43 antibodies were purchased from Merck Ltd.
(Tokyo, Japan). Kamishoyosan (TJ24), Shakuyakukanzoto
(TJ68), and Goshajinkigan (TJ107) were purchased,
along with their 3D–HPLC charts, were provided by
TSUMURA & CO. (Tokyo, Japan). We purchased MTT
(3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, yellow tetrazole) from Wako (Osaka, Japan)
and anti-neurofilament light protein (NF-L) antibodies
from Nova Biomedical (Waltham, USA). We purchased
antibodies targeting phospho-Akt (Ser473), Akt, Phospho-
p44/42 extracellular signal-regulated kinase (Erk)1/2
(Thr202/Tyr204), Erk1/2, and β-actin, as well as 2-(4-
Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydro-
chloride (LY294002) and 1,4-diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio] butadiene (U0126) from Cell
Signaling Technology Japan (Tokyo, Japan).
Preparation of TJ24, TJ68, and TJ107 (kampo medicines)
We added 2.5 g of each granule-based formulation to
100 mL boiling water and allowed the samples to dissolve
as much as possible (Table 1). After filtering the insoluble
material, we centrifuged the mixtures at 10,000×g for
20 min at 25 °C and collected their supernatants. These
were diluted with culture medium to 1 mg granule-based
formulation/mL (per manufacturer’s recommendation) for
this experiment.
Cell culture
Rat adrenal pheochromocytoma cells (PC12 cells) were
maintained on collagen I-coated dishes or plates, and
cultured at 37 °C in a humidified 5% CO2/air atmosphere.
Cells were cultured in culture medium containing DMEM
plus 10% FBS, 5% HS, and 1% PC/SM. Cells were differenti-
ated in DMEM containing 0.5% FBS, 1% HS, 1% PC/SM,
and 50 ng/mL NGF (differentiation medium) for 72 h; after
which they were plated at a density of 1.0 × 104 cells/cm2
and incubated for 24 h. A549 cells, derived from lung
tumor tissue, were plated at a density of 1.5 × 104 cells/cm2
in DMEM containing 10% FBS, and 2% PC/SM. A549 cells
were incubated for 3 days after seeding, then used for ex-
perimentation. To model neuropathy in the cell lines, pacli-
taxel (paclitaxel; 0–100 μM) diluted in culture medium was
added to the medium of differentiated PC12 cells for 24 h.
Table 1 Components of the kampo medicines TJ24, TJ68, and TJ107
Extractive component of kampo medicine
TJ24 ①Bupleurum Root (1.5 g) ②Paony Root (1.5 g) ③Atractylodes
Lancea Rhizoma (1.5 g) ④Poria Sclerotium (1.5 g) ⑤Japanese
Angelica root (1.5 g) ⑥Moutan Bark (1 g) ⑦Gardenia Fruit (1 g)
⑧Glycyrrhiza (0.75 g) ⑨Ginger (0.5 g) ⑩Japanese Mint (0.5 g)
TJ24 (7.5 g) contains dryness extract (2.0 g) of mix
herbal medicine for the percentage following.
TJ68 ①Paony Root (1.5 g) ②Glycyrrhiza (1 g) TJ68 (7.5 g) contains dryness extract (1.25 g) of mix
herbal medicine for the percentage following.
TJ107 ①Rehmannia Root (5 g) ②Alisma Rhizome (3 g) ③Achyranthes
Root (3 g) ④Poria Sclerotium (3 g) ⑤Cornus Fruit (3 g) ⑥Moutan
Bark (3 g) ⑦Dioscorea Rhizome (3 g) ⑧Cinnamon Bark (1 g)
⑨Plantago Seed (3 g) ⑩Aconitie Root (1 g)
TJ68 (7.5 g) contains dryness extract (4.5 g) of mix
herbal medicine for the percentage following.
Kampo medicines were diluted with culture medium to 1 mg/mL, per manufacturer’s recommendations
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MTT assay
For the MTT assay, differentiated cells were incubated
with 0.1–100 μM paclitaxel for 24 h in PC12 cells. A549
cells were incubated with 100 μM paclitaxel and either
TJ24 or TJ68 for 24 h. After washing cells once with
DMEM, they were incubated in 0.5 mg/mL MTT for
4 h, and then lysed in 500 μL DMSO. For each well,
200-μL supernatant was transferred to a 96-well plate,
and absorbance at 570 nm measured using a microplate
reader (TECAN InfiniteF50R) [8].
Evaluation of neurite growth
Cells were captured using phase contrast microscopy
(NIKON ECLIPSE TS100) and Digital Sight (NIKON
DS-Fi2). Images were imported to ImageJ (NIH, Baltimore,
Maryland, USA) to measure neurite length, which was de-
fined as the total length of the neurite cylinder axis. The
ratio of neurites to number of cells in the picture was also
measured. Images were captured following the incubation
of PC12 cells in differentiation and culture medium for
24 h; following the incubation of differentiated cells with
0.1–100 μM paclitaxel for 24 h in PC12 cells; and fol-
lowing the incubation of differentiated cells exhibiting
paclitaxel-induced neurite retraction (1 μM) in differen-
tiation medium with TJ24, TJ68, and NGF for 72 h
(without paclitaxel).
Western blot analysis
PC12 cells were rinsed with DMEM and lysed in ice-cold
lysis buffer consisting of 20 mmol/L Tris–HCl (pH 7.5),
150 mmol/L NaCl, 1 mmol/L Na2EDTA, 1 mmol/L
EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophos-
phate, 1 mmol/L β-glycerophosphate, 1 mmol/L sodium
orthovanadate, 1 μg/mL leupeptin, and 1% phenylmethyl-
sulfonyl fluoride; lysed cells were then homogenized. After
boiling for 5 min, equal amounts (20 μL) of the protein
samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis using 10% gels, and the
proteins were then transferred onto nitrocellulose mem-
branes at room temperature. The blots were probed using
their respective antibodies (at 4 °C overnight), followed by
the corresponding secondary antibody (room temperature,
1 h). Phosphorylated ERK1/2, ERK1/2, Phosphorylated
Akt, and Akt antibody were diluted in 1% BSA/TBS-T
(1:1000). Secondary antibodies were diluted in 1% skim
milk/TBS-T (1:2000). GAP-43 and β-actin antibody were
diluted in 1% skim milk/PBS-T (1:500, 1:1000), while sec-
ondary antibodies were diluted in 1% skim milk/PBS-T
(1:1000). NF-L antibody and its secondary antibody were
diluted in 1% skim milk/PBS-T (1:1000). Blots were devel-
oped using ECL Western Blotting Detection Reagent (GE
Healthcare Japan) and quantified using ImageJ. These ex-
periments were conducted at the time of neurite length
measurement.
Fig. 1 Paclitaxel (1 μM) induced neurite retraction without cytotoxicity in PC12 cells. We evaluated cell viability and neurite length after applying
varying concentrations of paclitaxel to PC12 cells. A total of 1 μM paclitaxel preserved the PC12 cells based on MTT assay, but still caused neurite
regression compared with NGF application only (a, b, c). Protein expression of the neuronal differentiation markers GAP-43 and NF-L, decreased
significantly after addition of 1 μM paclitaxel (d, e). Results (mean ± S.E.) are representative of three independent experiments (n = 3). **p < 0.01,
*p < 0.05. NGF: nerve growth factor; GAP-43: growth-associated protein 43; NF-L: light neurofilament; SE: standard error
Konaka et al. Journal of Pharmaceutical Health Care and Sciences  (2017) 3:20 Page 3 of 8
Amplite colorimetric acetylcholinesterase assay
The Amplite kit quantifies thiocholine produced from
cholinesterase-mediated acetylthiocholine hydrolysis using
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB). To ascertain
the function of differentiated cells, we verified the ability
of TJ24, TJ68, and NGF (without paclitaxel) to recover the
release of acetylcholine from cells with paclitaxel-induced
neurite retraction. The manufacturer’s recommended
protocol was followed; briefly, 50 μL of acetylthiocholine
reaction mixture (assay buffer, DTNB, acetylthiocholine)
was added to each cell lysate sample. The reaction was in-
cubated for 20 min at room temperature and protected
from light [9]. The absorbance at 410 ± 5 nm was mea-
sured with the microplate reader (TECAN InfiniteF50R).
Statistical analysis
Results are expressed as mean ± S.E. Differences be-
tween groups were analyzed using Dunnett’s t-test. In all
cases, p < 0.05 was considered statistically significant.
Results
Paclitaxel-induced neuropathy
Varying concentrations of paclitaxel were added to PC12
cells, following which cell viability and neurite length
were evaluated. One (1) μM paclitaxel preserved the
PC12 cells based on the MTT assay, though still produced
regression of neurites equal to that observed following
withdrawal of NGF (Fig. 1a–c). Protein expression of the
neuronal differentiation markers GAP-43 and NF-L de-
creased significantly after application of 1 μM paclitaxel
(Fig. 1d, e). Thus, we used a 1-μM paclitaxel dose for all
subsequent experiments to represent paclitaxel-induced
neuropathy.
TJ24 and TJ68 promoted NGF-induced neurite outgrowth
after paclitaxel-induced neuropathy
We compared neurite recovery for each formula after
72 h of exposure to paclitaxel-induced neuropathy. In
terms of neurite length, treatment with NGF and TJ24
or TJ68 promoted significantly greater neurite outgrowth
than NGF alone (Fig. 2a). A statistically significant in-
crease in the expression of both GAP-43 and NF-L was
also observed for the combinations of NGF and TJ24 or
TJ68 (Fig. 2b, c). Moreover, both combinations increased
acetylcholinesterase activity significantly relative to NGF
alone (Fig. 2d). TJ107, however, failed to significantly
affect any of the tested parameters. These data indicate
that TJ24 or TJ68 in combination with NGF enhanced re-
covery after paclitaxel-induced neurite regression.
Fig. 2 TJ24 and TJ68 with NGF improved paclitaxel-induced neuropathy morphologically and functionally. Recovery of neurites from paclitaxel-induced
regression after 72 h exposure to TJ24, TJ68, NGF plus TJ24, TJ68, or TJ107 was assessed. In terms of neurite length (a), expression of GAP-43 (b), NF-L (c),
and acetylcholine esterase concentration (d), treatment with NGF and TJ24 or TJ68 promoted neurite outgrowth significantly compared to NGF alone.
Results (mean ± S.E.) are representative of three independent experiments (n = 3). * p < 0.05. NGF: nerve growth factor; GAP-43: growth-associated
protein 43; NF-L: light neurofilament; SE: standard error
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TJ24 and TJ68 alter NGF-induced phosphorylation
To begin revealing the mechanism underlying the effects
of TJ24 and TJ68, we measured neurite outgrowth after
incubation with NGF alone, and with TJ24 or TJ68, for
72 h; we then compared these data to those collected in
the presence of U0126 or LY294002, ERK1/2, and Akt
inhibitors, respectively or both. Incubation with TJ24 or
TJ68 promoted significantly greater neurite outgrowth
than NGF alone (Fig. 3a, b). Both U0126 and LY294002
inhibited the promotion of neurite outgrowth induced
by TJ24 or TJ68 (Fig. 3a, b). Further, simultaneous treat-
ment with U0126 and LY294002 inhibited neurite out-
growth more strongly than treatment with a single agent
(Fig. 3c). These results suggest that Erk/Akt signaling ac-
tivity is affected by these kampo formulas.
TJ24 and TJ68 promoted neurite outgrowth through
NGF-induced phosphorylation of ERK1/2 and Akt
We also investigated whether TJ24 and TJ68 increased
phosphorylation of ERK1/2 and/or Akt in the process of
promoting neurite outgrowth by comparing the proportion
of phosphorylated ERK1/2 and Akt to their respective non-
phosphorylated forms. TJ24 and TJ68 both significantly en-
hanced NGF-mediated phosphorylation of ERK1/2 and Akt
(Fig. 4), indicating that both ERK1/2 and Akt signaling were
altered.
TJ24 and TJ68 did not affect paclitaxel-induced anticancer
efficacy
We sought to determine whether the kampo formulas
also reduced the antitumor effectiveness of paclitaxel by
performing a cytotoxicity assay in A549 (lung tumor-
derived) cells. We compared cell viability after incubation
for 24 h with TJ24 or TJ68 in the presence or absence of
100 μM paclitaxel [10]. Neither TJ24 nor TJ68 reduced
the cytotoxic efficacy of paclitaxel in A549 cells (Fig. 5).
Discussion
Though research has revealed that paclitaxel-induced
neuropathy worsens with increasing frequency of adminis-
tration, no adjunct therapies or altered paclitaxel adminis-
tration schedules have emerged to combat the associated
neuropathic damage. In clinical environments, systemic
pregabalin or mecobalamin therapy is used to reduce
neuropathic pain, but the effectiveness of such regimens
remains questionable [11, 12]. Furthermore, pregabalin
has its own potentially significant side effect—kidney
dysfunction—which can also force the discontinuation
of chemotherapy. Recent reports have suggested that
TJ68 was effective against paclitaxel-induced neuropathy,
and that TJ107 was effective against oxaliplatin-induced
neuropathy, respectively, though these reports have pro-
vided limited evidence and little or no mechanistic
Fig. 3 NGF with TJ24 or TJ68 alters both the ERK1/2 and Akt pathways. We analyzed neurite outgrowth after treatment with NGF alone, NGF and
TJ24, or NGF and TJ68. Neurite outgrowth was also examined when the Erk1/2 inhibitor U0126, Akt inhibitor LY294002, or both were added to
each previous condition for 72 h. Incubation with TJ24 or TJ68 promoted neurite outgrowth significantly compared to NGF alone (a, b). 0126 or
LY294002 alone inhibited the promotion of neurite outgrowth by TJ24 or TJ68 partially. When both inhibitors were administered together, neurite
outgrowth was significantly suppressed even following the addition of TJ24 or TJ68 (c). Results (mean ± S.E.) are representative of three independent
experiments (n = 3). *p < 0.05 vs NGF alone, †p < 0.05 vs U0126 or LY294002, NGF: nerve growth factor; Erk1/2: extracellular signal-regulated kinase 1/2;
SE: standard error
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information [5, 7]. Therefore, we felt it necessary to study
these effects further utilizing a model of paclitaxel-
induced neurite retraction due to its relative ease of use as
well as its capacity for studying the potential mechanisms
involved.
We first determined an optimal dose of paclitaxel that
did not affect cell viability but induced significant neurite
retraction, following which we observed that TJ24 and
TJ68 in combination with NGF significantly recovered
neurite outgrowth. We also noted that both morphological
and functional markers were improved. However, the
TJ107/NGF combination was ineffective. Our results differ
from those of a previous study that analyzed oxaliplatin-
induced neuropathy, though it is important to note that
paclitaxel and oxaliplatin are very different drugs and
induce neuropathy differently [13]. Oxaliplatin impairs
the nerve cells themselves, whereas paclitaxel impairs
the neuraxon [14].
Based on the need to combine NGF with TJ24 or TJ68,
and the previous finding that Yokukansan extended neur-
ite outgrowth via ERK1/2 and Akt phosphorylation [15],
we focused our attention on this pathway. Although
NGF-induced neurite outgrowth in PC12 cells is associ-
ated with activity of the p75NTR and TrkA pathways,
this process is primarily controlled by the ERK1/2 and
Akt pathways [16]. We revealed that TJ24 or TJ68 pro-
moted neurite outgrowth induced by NGF, but it was
inhibited partially when ERK1/2 and Akt were blocked
by U0126 and LY294002, respectively. In addition, we
revealed that neurite outgrowth induced by TJ24 and
TJ68 was inhibited more strongly when U0126 and
LY294002 were treated at the same time. These results
also indicated that Erk and Akt work cooperatively to
promote neurite outgrowth induced by TJ24 and TJ68.
Thus, it seems likely that the kampo medicines promoted
neurite outgrowth via activation of both the ERK1/2 and
Akt pathways [17]. Indeed, we found further evidence that
phosphorylation of both ERK1/2 and Akt is increased, in
correlation with our other findings (Fig. 6). However, we
have some limitations in this study. We used PC12 cells as
neuron model, but it was different from a peripheral nerve
cell a little strictly. Although PC12 cells are often used as
an in vitro model of neurons in the peripheral nervous
system, further investigation in dorsal root ganglion cells
is required to determine the effects of TJ24 and TJ68 in
vivo [18, 19]. When taking orally, we need to consider in-
fluence by metabolism in the body, but the consideration
can’t be performed in this experiment. The drug dispos-
ition of kampo and specification of a single active ingredi-
ent remain unclear, and our results are limited to in vitro
Fig. 4 TJ24 and TJ68 promoted NGF-induced phosphorylation of Erk1/2 and Akt. We compared the proportion of phosphorylated Erk1/2 and Akt
to their respective non-phosphorylated forms. Both TJ24 and TJ68 significantly increased phosphorylation of Erk1/2 and Akt compared with NGF
alone. Results (mean ± S.E.) are representative of three independent experiments (n = 3). **p < 0.01, *p < 0.05. NGF: nerve growth factor; Erk 1/2:
extracellular signal-related kinase 1/2; SE: standard error
Fig. 5 TJ24 and TJ68 did not affect paclitaxel-induced cytotoxicity in
lung tumor-derived cells (A549). Cell viability after incubation for 24 h
with TJ24 or TJ68 in the presence or absence of 100 μM paclitaxel was
measured. Neither TJ24 nor TJ68 alone influenced cell viability, and
reduced paclitaxel induced-antitumor efficacy in A549 cells compared
to control. Results (mean ± S.E.) are representative of three independent
experiments (n = 3). ** p < 0.01. SE: standard error
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analysis. Further study is required in order to conclusively
identify the active ingredient and clarify the efficacy of
kampo medicines in vivo, as only peony root and licorice
(Glycyrrhiza sp.) are common to TJ24 and TJ68. Of these,
Yokukansan does not contain peony; thus, we hypothesize
that licorice is the ingredient that requires further study.
Because the clinical use of TJ24 or TJ68 would be concur-
rent with paclitaxel chemotherapy, it is also necessary to
determine if either formula would interfere with its thera-
peutic effectiveness.
Though further work must be done to confirm our data,
we noted that neither formula interfered with the ability
of paclitaxel to kill A549 (tumor cell line) cells [20].
Conclusions
Kamishoyosan or Shakuyakukanzoto promotes neurite
outgrowth with NGF via increasing the proportion of
phosphorylated Erk1/2 and phosphorylated Akt in PC12
cells. We conclude that Kamishoyosan or Shakuyakukanzoto
could likely be used safely and effectively in conjunction with
paclitaxel chemotherapy, to rescue paclitaxel-induced
neuropathy and ensure that the full round and dose in-
tensity of chemotherapy is delivered to patients.
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